Novo Nordisk’s (NOVOB DC) oral semaglutide demonstrates potential to be the first oral GLP-1 RA for children and adolescents with type 2 diabetes; trial demonstrated a statistically significant and superior reduction in blood sugar by 0.83% vs placebo
Context
Novo Nordisk's recent trial results for oral semaglutide, aiming to be the first oral GLP-1 receptor agonist for children and adolescents with type 2 diabetes, show promise with a significant reduction in blood sugar versus placebo. This advancement not only supports Novo's pipeline but may also bolster its competitive stance in the diabetes market, potentially influencing investor sentiment and further product development.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#EUROPEAN EQUITIES